ILARIS150mg

ILARIS (canakinumab) 150mg/ml by Novartis is a breakthrough fully human monoclonal antibody that selectively binds and neutralizes interleukin-1 beta (IL-1β), a master pro-inflammatory cytokine driving autoinflammatory cascades. As the only anti-IL-1β biologic with FDA approval across six autoinflammatory indications, Ilaris has transformed treatment of rare inflammatory conditions. FDA-approved for Cryopyrin-Associated Periodic Syndromes (CAPS including FCAS and MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease (AOSD), and Periodic Fever Syndromes (FMF, TRAPS, HIDS/MKD). The CANTOS trial (10,061 patients) also demonstrated cardiovascular benefit, reducing MACE by 15%. Working through licensed Turkish pharmacy channels, we provide authentic Novartis ILARIS with validated cold chain handling (2-8°C), batch and expiry documentation, and a written quote against a prescription, usually within 24 hours for hospitals, rheumatology clinics, and pharmaceutical distributors worldwide.